AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05624866
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
Trial: NCT05430048
Drug: nasal Desmopressin
RxNorm normalized name: desmopressin Nasal Solution
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
Trial: NCT01304628
Drug: PL-3994
RxNorm normalized name: PL-3994
DrugBank: PL-3994 (DB15355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous PL-3994, single dose, 4 escalating dose groups
Trial: NCT04778787
Drug: Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
Trial: NCT04991350
Drug: Intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
Trial: NCT04991350
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
Trial: NCT05350124
Drug: Tocopherol
RxNorm normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin E (400 IU) capsule
Trial: NCT06213519
Drug: S-1, Oxaliplatin sintilimab HIPEC
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
Trial: NCT05247476
Drug: L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
Trial: NCT05247476
Drug: L-T4+T3 (thyroid tablet)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
Trial: NCT05241054
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
Trial: NCT05241054
Drug: Nitroglycerine
RxNorm normalized name: Nitroglycerine
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
Trial: NCT05241054
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
Trial: NCT05241054
Drug: Atracurium Besylate
RxNorm normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
Trial: NCT05241054
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
Trial: NCT05241054
Drug: Lactated Ringers
RxNorm normalized name: lactated ringers
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
Trial: NCT05241054
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
Trial: NCT05101915
Drug: RESP301
RxNorm normalized name: RESP301
DrugBank: RESP301 (DB16497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled IMP delivered via nebulisation
Trial: NCT05582590
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
Trial: NCT04842526
Drug: Anlotinib and irinotecan combined with temozolomide
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
Trial: NCT05813626
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
Trial: NCT04988425
Drug: TNFα Monoclonal Antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
Trial: NCT04988425
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 500mg of methylprednisolone immediately after admission before surgery.
Trial: NCT04988425
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of the same volume of saline immediately after admission before surgery
Trial: NCT02846857
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Trial: NCT02846857
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Trial: NCT04243122
Drug: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
RxNorm normalized name: apixaban 2.5 MG Oral Tablet [Eliquis]
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
Trial: NCT04243122
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81mg once per day for 6 months Then treated \& followed up as per standard of care
Trial: NCT05236621
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg pomalidomide capsules administered orally
Trial: NCT05236621
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg dexamethasone tablets administered orally
Trial: NCT06261684
Drug: Intralesional Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional Acyclovir in plantar warts
Trial: NCT05201911
Drug: 124I-AT03
RxNorm normalized name: 124I-p5+14
DrugBank: Iodine I-124 Evuzamitide (DB18394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
Trial: NCT04989985
Drug: Oxaliplatin+S-1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w
Trial: NCT04989985
Drug: Sinitilimab+oxaliplatin+S-1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w
Trial: NCT06340165
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.
Trial: NCT00010686
Drug: Dietary Phytoestrogens
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06249581
Drug: AUX-001 40mg once-daily
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
Trial: NCT06319235
Drug: IMP
RxNorm normalized name: Impact
DrugBank: Topramezone (DB14826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
Trial: NCT05453045
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet administration after a meal contaning approximate 15 g of fat
Trial: NCT05178485
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved drug
Trial: NCT06527534
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
Trial: NCT06527534
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
Trial: NCT04975100
Drug: Sarcosine and SSRI
DrugBank: Sarcosine (DB12519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
Trial: NCT00000897
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06465992
Drug: Bupivacaine Hcl 0.75% Inj
RxNorm normalized name: BUPIVACAINE HCL 0.75% INJ
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
Trial: NCT06465992
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
Trial: NCT06488794
Drug: colistimethate sodium
RxNorm normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for 3 days for eligible ventilated children starting from day 3 of mechanical ventilation.
Trial: NCT05817474
Drug: lidocaine (2 %) 2 ml and tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
Trial: NCT06201871
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
Trial: NCT06544447
Drug: Hyaluronic acid eye drops
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Trial: NCT05032118
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titratable ketamine infusion + low fixed-dose propofol.
Trial: NCT05032118
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care titratable propofol infusion.
Trial: NCT05320016
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
Trial: NCT04842981
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Trial: NCT04842981
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Trial: NCT05177731
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally by mouth
Trial: NCT05177731
Drug: Decitabine for Injection
RxNorm normalized name: Decitabine for Injection
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05177731
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05177731
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05177731
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally by mouth
Trial: NCT05375435
Drug: dual-therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
Trial: NCT03988998
Drug: Radiofrequency ablation with radiotherapy
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiofrequency ablation with radiotherapy
Trial: NCT04827589
Drug: Tirabrutinib
RxNorm normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT06329674
Drug: A51R2
RxNorm normalized name: Amoxicillin/Clavulanic Acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT06329674
Drug: A51R3
RxNorm normalized name: Amoxicillin/Clavulanic Acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT06385847
Drug: Zoladex
RxNorm normalized name: Zoladex
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 3.6 mg subcutaneous Zoladex
Trial: NCT05222035
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
Trial: NCT05222035
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
Trial: NCT05266014
Drug: tinlarebant
RxNorm normalized name: Tinlarebant
DrugBank: Tinlarebant (DB17832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months.
Trial: NCT05024422
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
Trial: NCT04957329
Drug: Xalatan
RxNorm normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eye drop
Trial: NCT04957329
Drug: Monoprost
RxNorm normalized name: dinoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eye drop
Trial: NCT05097209
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
Trial: NCT05097209
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
Trial: NCT05097209
Drug: Induction Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
Trial: NCT05097209
Drug: Concurrent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Trial: NCT05893680
Drug: Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)
RxNorm normalized name: sodium chloride 9 MG/ML [Broncho Saline]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
Trial: NCT06180941
Drug: magnesium sulfate.
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Trial: NCT06180941
Drug: clonidine.
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Trial: NCT00002122
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002122
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04921878
Drug: Mitoxantrone Hydrochloride Liposome injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
Trial: NCT05708300
Drug: Mepolizumab 100 MG [Nucala]
RxNorm normalized name: mepolizumab 100 MG [Nucala]
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection once a month
Trial: NCT00269997
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06468267
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
Trial: NCT00000850
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000850
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no